on will product of will webcast. I then results. fourth Thank thank and highlight who you of some financial portfolio. we’ve us turn to to productive will with strategic start call We and I quarter to begin providing like live our update, our a by the progress it review who you, are I’d made joining Jeff, those then over today had a Paula, busy the via you very XXXX. to
XX% took and to a X, was accomplishments full stake. exchange that the important the ownership from our completion XXX% to us which of most the January reorganization during XXXX our ThermoGenesis enabled fourth share agreement of of increase on One effect quarter,
commercialization XX% equity of XX% is called Bay Bio. a accomplished shares exchanged was six subsidiary launch solely a City of slightly while remaining cell-based is broadly, wholly-owned which AXP CARTXpress or to and to Corp. created commercialize includes cells. May acquisition City through The stem launched of the remaining more for t-cells our reorg, develop CAR-T and CARTXpress ThermoGenesis and further system. addition newly on devices proprietary of technology this subsidiary Bio. a banking, owns including Bay and As automation CAR-TXpress new in the Capital’s cellular receptor result is for the antigen the the technologies POCXpress. cell now ownership, ThermoGenesis drugs, point-of-care therapies. CAR-TXpress ThermoGenesis on mission recently Cesca. development and and of manufacturing most arrangement or XX% CAR-TXpress the after focused More the medical focusing XXXX a automated of months platform ThermoGenesis ThermoGenesis platform, large-scale of This follows commercialization of immunotherapy developing applications chimeric development Bio of than commercializing only the CARTXpress This of ThermoGenesis and is of the AutoXpress,
device of of the processing clinical ourselves as supporting its a cellular POCXpress, player As step division goal indicates, cells the as are application market. all a being autologous and one for defying Today, point-of-care name moves our key applications. and restructuring having division. clearly and meeting clinical to of AutoXpress closer a cell-based various used focused cell in needs is we banking is This ever-growing medical stem therapeutic reminder, us a storage, on for
meantime, shareholders. on the most how for me execution is quarter. we One the of of let of asset our options to ThermoGenesis tangible for In fourth in its made explore can ThermoGenesis realize value progress the report highest and capitalize effectively the priority the on strategy
become and of is ThermoGenesis the and therapy increase the partner CAR-T manufacturers. to for goal acceptance and visibility the choice continuous of Our market in researchers cell
better t-cell and based think market from you we As eight for viability cell time technology and cell for CAR-T cell-based and addresses recovery, need cell hours sorting current our on over activation target to to manufacturing providing modular that and manufacturing, We to or merely the ficoll-based is CAR-TXpress overall a our uses therapeutics, processing and system on dramatically improvement for BACS platform’s of that efficiency. ability robust dramatic continue cancer. the high It buoyancy-activated platform isolation, unmet or a antigen time, this cell their cell large-scale purification educate therapies method t-cells, closed improve revolutionary is especially may know, magnetic-beads while for point to chimeric two. reduce as CAR-TXpress CAR-T
the of As declined treat last price the challenges that two recommended drug CAR-T its a European Service, but summer, U.S. difficult to we form cancers, treat knowledge, In gene justifiable. an to The for the per list Commission rationale, help major for exciting cost coverage cost. resolve, noticed to potential pharmaceutical patient the Health to example of not therapy a government companies’ is that the blood of due can cancer the National was very XXX,XXX. stating aggressive
related fast-evolving on ability of partner full new committed of field. the to cellular variabilities. we use advancements steps transformation becoming besides wholly the In in become immunotherapy providing overcome that batch-to-batch its as we a to for advantage personalized therapy, the remain choice the nature addition, this with is this of the of manufacturing cell-based variability and technology reducing the key solution, process think cancer allows remains can because will service automation a manufacturers, to of We It emphasis costs, the contribute the manufacturing critical due highly our which in field our to recognized therapy, pharmaceutical key high. to because
use positive modular systems. product And of to adopted both responses system, CAR-TXpress the from our and other can be that we academia continue X-WASH cell-based to receive gene flexibility with X-LAB CAR-TXpress the the and and We including for stem and the therapies. inherited design platform given easily believe the industry line,
have larger CMOs. reception large we bought technology, positive major systems, looking XX institutions and testament companies including institutes, of more buying research our to to top pharmaceutical or than our As a the
to of be value that appreciated, accomplished cell the this continues have with this it bears limited we So reminding support. and system
product cord We are channels revolutionary our stem has to expand devices global support a the positive that lies In extracting launching sales of This banks II of AXP could business by cell assets. that broadly The device from also in our The is leading used other model fourth our world. to institutes different value this continues AXP U.S. next-generation platform direction XXX(k) area, the by now technology. November. the and around of advantage been for values a new We’ll trend line automation quarter. a in global our in multi-pronged help of approach technologies. sales AXP cell and replacement our clearance II industry looking continue stem market-leading blood in AXP received of our for FDA
directly technology In pharma will opportunities. into CDMO another development marketing X-Series companies, contract and and to service, addition CMO to and to or service expand products researchers ThermoGenesis manufacturing our work provide compelling
the exclusive in capture would the its IncoCell while been to with therapeutics of Boyalife for percentage two-thirds, of and double-digit on revenue. and a company using the a allows market. For provide to products for the for ThermoGenesis CDMO be business model, basis, has of IncoCell we its mitigate to in cost our contract Group, collaboration co-development CDXX cost on we partnerships we saving Today, still CAR-T operation X-Series able exchange market. Through the to current arena. compared technology Chinese to Such up an to initial a helps gross the used developers Inc, co-develop investment, service risk kit offer affiliated believe collaboration development of reduce an of capital manufacturing opportunity humanized
pursue selected the markets, additional in opportunities CMO, to CDMO including U.S. continue will We
you Now, we goals let side. made on product towards for the our me the outline progress
the As XXX(k) November, noted blood for AutoXpress proprietary ago, received II clinical few AXP from platform in ThermoGenesis for its FDA banking. a moments clearance
As in including many important you stem a next-generation and of rate cell represents the excess our highest introduced system proprietary in processing in AXP advancement automated XpressTRAK cord the station know, achieved in generation software II industry. that biggest years. enhancement first recovery to blood the dock of XX%, together The the device, may AXP consistently
will began the significant immuno-oncology an development market field, clearance play already in XXX(k) of particularly therapeutics, to in where clinical we Our cell-based us support important help role.
File, to who can scale clean rate equipped As purification Control principal quarter the their greater use device of improve purpose with noted this how a to Orthohealing and even X-LAB, protect Follow Master on an the months assembly its Docking requirement processing FDA intellectual our supply we it the rising with a chain supply to the demand in System. and comply the our Device the and announced of January, quality provide X-Series. with call, keep want continued. example – want first for room allows disclosure, to – IND about include our X,XXX in-house or much our systems Module agreement manufacturing The regulatory to in of our that of allow to within Management. cell in important, automated momentum X-LAB products to foot square which cell few with Cesca’s took and filed or the cartridge, a In third-party, of we the while MNC the X-BACS – them MAF, service. and Last properties. is in-house a the activation gives PXP Equally – physicians, we DMF by selection and and giving now the ThermoGenesis the processing Compared their completed our is last Station ability close we month, quarter to to X-WASH This automated utilize covers investigators for devices. announced, to device. is disposables over processing the occurs. customer better control maintain ThermoGenesis processing networks We of pace of target support this cell detail, INDs the both filing us us of higher XXXX, plan Center
precise concentrate this physician their marrow. benefit network particular can the of So is a that they this their prepare Orthohealing autologous patients. bone cell Method unique from instance, providing to In
a electrical of received been – Docking platform’s clearance labeling for X-LAB, cells and X-Series signifies System, mark, ThermoGenesis PXP that have international a XXXX. all also – of February, beginning XX% goal We top cost the the control our in turn deliver combines bone also CAR-TXpress or anticipated keeping flow marrow. and we’ll which point-of-care We standpoint, standards tested harvesting Health diligence tested Rheinland Module over the of targets achieving in needed with now, purified of for in platelets From with and with have our XXXX Jeff? that System from cost all Station comply should received reduction to anticipate Control financial to with PXP let to attention to for the for safety. X-WASH as from the expenses financial growth Canada report. the blood And measures and approval bone from the for continue me And of mononuclear implement in XXXX. positive revenue call cash help in Jeff our
